NPS, GSK sign new calcilytics agreement
Under the new deal, NPS will be responsible for filing applications for two of GSK’s experimental calcilytic compounds, SB-423557 and SB-423562 (NPSP790 and NPSP795). The new agreement will
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.